Raises FY23 revenue to $425M-$445M from $385M-$410M. Consensus is for FY23 EPS $3.31 and for revenue $406.41M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ANIP:
- ANI Pharmaceuticals Reports Record Second Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance
- ANIP Earnings this Week: How Will it Perform?
- ANI Pharmaceuticals to Discuss Second Quarter 2023 Financial Results on August 9, 2023, at 8:30 a.m. ET
- ANI Pharmaceuticals price target raised to $62 from $59 at Guggenheim
- ANI Pharmaceuticals price target raised to $60 from $52 at Truist
